Claudin-6: A novel receptor for CPE-mediated cytotoxicity in ovarian cancer

Oncogenesis

Volumn 1, Issue 11, 2012, Pages

  Lal Nag, M ^a   Battis, M ^a   Santin, A D ^b   Morin, P J ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

claudin; clostridium perfringens enterotoxin; ovarian cancer; therapy

Indexed keywords

CLAUDIN 3; CLAUDIN 4; CLAUDIN 6; ENTEROTOXIN;

ARTICLE; CANCER CELL CULTURE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR SPHEROID;

CLOSTRIDIUM PERFRINGENS;

EID: 84869436596     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.32     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bast Jr. R.C., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
3. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374: 1371-1382.
4. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65: 9603-9606. (Pubitemid 41541431)
5. Kominsky SL. Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 2006; 8: 1-11. (Pubitemid 44184255)
6. Valle B, Morin PJ. Claudins in cancer biology. Curr Top Membr 2010; 13: 293-333.
7. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000; 60: 6281-6287.
8. Rangel LBA, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003; 9: 2567-2575. (Pubitemid 36842098)
9. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithe-lium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004; 112: 14-25. (Pubitemid 39249487)
10. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 2006; 103: 405-416. (Pubitemid 44602159)
11. Kleinberg L, Holth A, Fridman E, Schwartz I, Shih Ie M, Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol 2007; 127: 928-937.
12. Dahiya N, Becker KG, Wood 3rd WH, Zhang Y, Morin PJ. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS ONE 2011; 6: e22119.
13. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 1997; 272: 26652-26658. (Pubitemid 27458889)
14. Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M et al. Treatment of chemotherapy-resistant human ovarian cancerxenografts in C.B-17/SCID mice by intraperitoneal administration ofClostridium perfringens enterotoxin. Cancer Res 2005; 65: 4334-4342. (Pubitemid 40775672)
15. Takahashi A, Kondoh M, Suzuki H, Yagi K. Claudin as a target for drug development. Curr Med Chem 2011; 18: 1861-1865.
16. Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I et al. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3-and-4-overexpressing tumors. Gene Ther 2012; 19: 494-503.
17. Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001; 121: 678-684. (Pubitemid 32822583)
18. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tightjunction proteins claudin 3 and 4.Am J Pathol2004; 164: 1627-1633. (Pubitemid 38529765)
19. Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ et al. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin Cancer Res 2007; 13: 3339-3346. (Pubitemid 46944921)
20. Maeda T, Murata M, Chiba H, Takasawa A, Tanaka S, Kojima T et al. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 2012; 72: 351-360.
21. Winkler L, Gehring C, Wenzel A, Muller SL, Piehl C, Krause G et al. Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3. J Biol Chem 2009; 284: 18863-18872.
22. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, Tsukita S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 2000; 476: 258-261. (Pubitemid 30410828)
23. Ling J, Liao H, Clark R, Wong MS, Lo DD. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem 2008; 283: 30585-30595.
24. Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007; 109: 1312-1322. (Pubitemid 46466558)
25. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
26. Wang L, Xue Y, Shen Y, Li W, Cheng Y, Yan X et al. Claudin 6: a novel surface marker for characterizing mouse pluripotent stem cells. Cell Res 2012; 22: 1082-1085.
27. Turksen K, Troy TC. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn 2001; 222: 292-300. (Pubitemid 32937601)
28. Anderson WJ, Zhou Q, Alcalde V, Kaneko OF, Blank LJ, Sherwood RI et al. Genetic targeting of the endoderm with claudin-6CreER. Dev Dyn 2008; 237: 504-512.
29. Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK et al. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol 2010; 20: 140-150.
30. Sullivan LM, Yankovich T, Le P, Martinez D, Santi M, Biegel JA et al. Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors. AmJSurg Pathol 2012; 36: 73-80.
31. Yafang L, Qiong W, Yue R, Xiaoming X, Lina Y, Mingzi Z et al. Role of estrogen receptor-alpha in the regulation of claudin-6 expression in breast cancer cells. J Breast Cancer 2011; 14: 20-27.
32. Rendon-Huerta E, Teresa F, Teresa GM, Xochitl GS, Georgina AF, Veronica ZZ et al. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse-and intestinal-type gastric adenocarcinomas. J Gastrointest Cancer 2010; 41: 52-59.
33. Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF, Rendon-Huerta EP. Claudin-6, 7, or 9 overexpression in the human gastric ade-nocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest 2011; 29: 1-11.
34. Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y et al. Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev 2010; 19: 186-194.
35. Mitchell LA, Koval M. Specificity of Interaction between Clostridium perfringens enterotoxin and Claudin-Family tight junction proteins. Toxins 2010; 2: 1595-1611.
36. Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE et al. Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. IntJMolSci 2011; 12: 1334-1358.
37. Workman P, Clarke PA, Al-Lazikani B. Personalized medicine: patient-predictive panel power. Cancer Cell 2012; 21: 455-458.